Idorsia Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	7.4yrs
Board average tenure	3.5yrs

Recent management updates

Recent updates

CEO

Idorsia has no CEO, or we have no data on them.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Andre Muller	Executive VP & CFO	7.8yrs	no data	0.056% CHF 81.1k
Martine Clozel	Executive VP & Chief Scientific Officer	7.8yrs	no data	6.79% CHF 9.9m
Guy Braunstein	Executive VP & Chief Medical Officer	no data	no data	0.11% CHF 157.9k
Alberto Gimona	Executive VP & Head of Global Clinical Development	5.8yrs	no data	0.0071% CHF 10.3k
Andrew Weiss	Senior VP and Head of Investor Relations & Corporate Communications	7.4yrs	no data	no data
Julien Gander	Senior VP	2yrs	no data	no data
Alexander Khatuntsev	Senior VP & Head of Global Human Resources	7.4yrs	no data	no data
Olivier Lambert	Senior VP & Head of Technical Operations	no data	no data	no data
Markus Riederer	Senior VP & Head of Drug Discovery Biology	no data	no data	no data
Christoph Boss	Senior VP & Head of Drug Discovery Chemistry	no data	no data	no data

7.4yrs

Average Tenure

59.5yo

Average Age

Experienced Management: 0RQE's management team is seasoned and experienced (7.4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Peter Kellogg	Non-Executive Director	3.5yrs	CHF 149.37k	0.020% CHF 29.5k
Jean-Paul Clozel	Chairman of the Board	less than a year	CHF 1.98m	19.04% CHF 27.8m
Joern Aldag	Non-Executive Director	4.5yrs	CHF 156.82k	0.021% CHF 30.8k
Felix Ehrat	Non-Executive Director	4.5yrs	CHF 174.78k	0.054% CHF 78.7k
Bart Filius	Non-Executive Director	less than a year	no data	no data
Mathieu Simon	Vice-Chairman & Lead Independent Director	5.5yrs	CHF 344.19k	0.069% CHF 100.3k
Sophie Kornowski-Bonnet	Non-Executive Director	1.5yrs	CHF 117.54k	0.012% CHF 17.7k
Sandesh Mahatme	Non-Executive Director	4.5yrs	CHF 172.30k	0.025% CHF 36.4k
Srishti Gupta	Non-Executive Director	3.5yrs	CHF 161.88k	0.025% CHF 35.8k

3.5yrs

Average Tenure

65yo

Average Age

Experienced Board: 0RQE's board of directors are considered experienced (3.5 years average tenure).

Idorsia Management

Management criteria checks 2/4

Key information

Recent management updates

Idorsia Ltd Approves Board Appointments

No independent directors

No independent directors

Recent updates

Idorsia's Once-Daily Tryvio (Aprocitentan) Is Now Available in the U.S., Advancing Treatment Options for Millions of Patients with Difficult-To-Control Hypertension

New minor risk - Shareholder dilution

Third quarter 2024 earnings released: CHF0.56 loss per share (vs CHF1.27 profit in 3Q 2023)

Idorsia Ltd Provides Earnings Guidance for 2024

Investor sentiment deteriorates as stock falls 17%

Investor sentiment deteriorates as stock falls 16%

Investor sentiment deteriorates as stock falls 15%

Investor sentiment deteriorates as stock falls 21%

Second quarter 2024 earnings released: CHF0.60 loss per share (vs CHF1.08 loss in 2Q 2023)

Idorsia Ltd to Report Fiscal Year 2024 Results on Feb 27, 2025

Idorsia Ltd Receives Approval from the European Commission for JERAYGO™

Idorsia Ltd Approves Board Appointments

New major risk - Revenue and earnings growth

Full year 2023 earnings released: CHF1.67 loss per share (vs CHF4.67 loss in FY 2022)

Idorsia Ltd to Report Nine Months, 2024 Results on Oct 29, 2024

New major risk - Share price stability

Idorsia Ltd Announces New Phase 3 Data with Aprocitentan for Patients with Resistant Hypertension Presents At the American Society of Nephrology Kidney Week 2023

Third quarter 2023 earnings released: EPS: CHF1.26 (vs CHF1.22 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Idorsia Ltd Updates Earnings Guidance for the Year 2023

New major risk - Financial position

Second quarter 2023 earnings released: CHF1.08 loss per share (vs CHF1.25 loss in 2Q 2022)

Idorsia Ltd to Report Q1, 2024 Results on Apr 25, 2024

Sosei Group Corporation (TSE:4565) entered into an agreement to acquire Idorsia Pharmaceuticals Japan Ltd/Idorsia Pharmaceuticals Korea Co., Ltd from Idorsia Ltd (SWX:IDIA) for JPY 65 billion.

Idorsia Launches Quviviq (Daridorexant) in Switzerland – A First-In-Class Treatment for Chronic Insomnia Disorder to Improve Both Nighttime Symptoms and Daytime Functioning

First quarter 2023 earnings released: CHF1.19 loss per share (vs CHF1.12 loss in 1Q 2022)

Idorsia Ltd Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released: CHF4.67 loss per share (vs CHF3.77 loss in FY 2021)

No longer forecast to breakeven

Idorsia Ltd Provides Earnings Guidance for the Year 2023

Idorsia Ltd to Report Q3, 2023 Results on Oct 24, 2023

Forecast to breakeven in 2025

Idorsia Ltd Submits New Drug Application to the US FDA for Aprocitentan for Treatment of Patients with Difficult-to-Control Hypertension

Idorsia Ltd Announces Long-Term Safety and Tolerability Results with Daridorexant in Patients with Insomnia Disorder Published in CNS Drugs

Idorsia Ltd Announces Swissmedic Approves QUVIVIQ (daridorexant) – A First-In-Class Treatment for Chronic Insomnia Disorder to Improve Both Nighttime Symptoms and Daytime Functioning

No independent directors

The Janssen Pharmaceutical Companies, in Collaboration with Idorsia Ltd, Announce Results from the Phase 3 Precision Study

The Janssen Pharmaceutical Companies, in Collaboration with Idorsia Ltd, Announce Results from the Phase 3 Precision Study

Third quarter 2022 earnings released: CHF1.22 loss per share (vs CHF0.83 loss in 3Q 2021)

Idorsia Ltd Provides Earnings Guidance for the Year 2022

Now 21% undervalued after recent price drop

Now 20% undervalued

Second quarter 2022 earnings released: CHF1.25 loss per share (vs CHF0.83 loss in 2Q 2021)

Idorsia Ltd to Report Q1, 2023 Results on Apr 25, 2023

Now 22% undervalued after recent price drop

Idorsia Ltd Announces Positive Phase 3 Study with Aprocitentan Demonstrates Significant Antihypertensive Efficacy in Patients with Resistant Hypertension

Idorsia Ltd Announces Phase 2A Study Results in Binge Eating Disorder

Full year 2021 earnings released: CHF3.77 loss per share (vs CHF3.12 loss in FY 2020)

No independent directors

Idorsia Ltd to Report Fiscal Year 2022 Results on Feb 07, 2023

Idorsia Ltd and Idorsia Pharmaceuticals Japan Announces Availability of Pivlaz™ (Clazosentan) to Physicians in Japan to Start Treating Asah Patients

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Idorsia Ltd Announces Revenue Guidance for Full Year 2022

Idorsia Receives US FDA Approval of QUVIVIQ (daridorexant) 25 and 50 mg for the Treatment of Adults with Insomnia

Third quarter 2021 earnings released: CHF0.83 loss per share (vs CHF0.83 loss in 3Q 2020)

Second quarter 2021 earnings released: CHF0.83 loss per share (vs CHF0.51 loss in 2Q 2020)

Idorsia to Present New Phase 3 Data on Daridorexant in Insomnia at Sleep 2021

Director has left the company

Director has left the company

First quarter 2021 earnings released: CHF0.63 loss per share (vs CHF0.92 loss in 1Q 2020)

Idorsia Ltd Announces US FDA Approves Ponvory (ponesimod) to Treat Adults with Relapsing Forms of Multiple Sclerosis

FDA Accepts the New Drug Application for Review of Idorsia’s Daridorexant for the Treatment of Adult Patients with Insomnia

Idorsia Ltd Announces Submission of New Drug Application to the Japanese Pharmaceuticals and Medical Devices Agency for Clazosenta

New 90-day low: CHF24.55

Revenue misses expectations

Full year 2020 earnings released: CHF3.12 loss per share (vs CHF3.76 loss in FY 2019)

Idorsia Ltd to Report Q3, 2021 Results on Oct 26, 2021

New 90-day high: CHF28.05

New 90-day low: CHF21.16

New 90-day low: CHF21.16

New 90-day low: CHF21.16

Idorsia Ltd to Report First Half, 2021 Results on Jul 27, 2021